<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493698</url>
  </required_header>
  <id_info>
    <org_study_id>SBP-9200-HBV-202</org_study_id>
    <secondary_id>2018-000607-16</secondary_id>
    <nct_id>NCT03493698</nct_id>
  </id_info>
  <brief_title>A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>F-star Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>F-star Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open-label, fixed sequence study to investigate the effect of&#xD;
      multiple oral dosing of Inarigivir Soproxil and a single oral dose of Midazolam in Healthy&#xD;
      Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Actual">August 27, 2018</completion_date>
  <primary_completion_date type="Actual">August 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (Cmax)</measure>
    <time_frame>Day 1 Treatment A and Day 19 Treatment D, respectively</time_frame>
    <description>Comparison of Cmax for midazolam between Treatments A and D.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (AUC0-t)</measure>
    <time_frame>Day 1 Treatment A and Day 19 Treatment D, respectively</time_frame>
    <description>Comparison of AUC0-t for midazolam between Treatments A and D.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (AUC0-inf )</measure>
    <time_frame>Day 1 Treatment A and Day 19 Treatment D, respectively</time_frame>
    <description>Comparison of AUC0-inf for midazolam between Treatments A and D.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Relevant Clinical Laboratory, Vital Signs, 12-lead ECG, or Physical Examination</measure>
    <time_frame>Day -1 to Day 20 and Follow-up (5-9 days post-treatment)</time_frame>
    <description>Safety and tolerability were measured via clinical laboratory evaluations, vital signs, 12-lead ECG, or physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Inarigivir After Single and Multiple Oral Doses in Healthy Subjects (AUC)</measure>
    <time_frame>Day 3 and Day 6 to 19</time_frame>
    <description>A summary of the main plasma PK parameters for inarigivir, Rp-SB 9000, Sp-SB 9000, and Rp-SB 9000 and Sp-SB 9000 combined after a single oral dose of 400 mg inarigivir on Day 3 (Treatment B) and after the last of 14 consecutive daily oral doses of 400 mg inarigivir from Day 6 to 19 (Treatment D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Inarigivir After Single and Multiple Oral Doses in Healthy Subjects (Cmax)</measure>
    <time_frame>Day 3 and Day 6 to 19</time_frame>
    <description>A summary of the main plasma PK parameters for inarigivir, Rp-SB 9000, Sp-SB 9000, and Rp-SB 9000 and Sp-SB 9000 combined after a single oral dose of 400 mg inarigivir on Day 3 (Treatment B) and after the last of 14 consecutive daily oral doses of 400 mg inarigivir from Day 6 to 19 (Treatment D)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Drug Interaction Potentiation</condition>
  <arm_group>
    <arm_group_label>Treatment A: Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive a single oral dose of 2 mg Midazolam on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B and C: Inarigivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3, Day 6-18</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: Inarigivir with Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive a single oral dose of 400 mg Inarigivir coa administered with a single oral dose of 2 mg Midazolam on Day 19</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam</description>
    <arm_group_label>Treatment A: Midazolam</arm_group_label>
    <arm_group_label>Treatment D: Inarigivir with Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inarigivir</intervention_name>
    <description>Inarigivir</description>
    <arm_group_label>Treatment B and C: Inarigivir</arm_group_label>
    <arm_group_label>Treatment D: Inarigivir with Midazolam</arm_group_label>
    <other_name>Inarigivir Soproxil, SB 9200</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gender : male or female&#xD;
&#xD;
          2. Age : 18-55 years, inclusive, at screening&#xD;
&#xD;
          3. Body mass index (BMI) : 18.0-30.0 kg/m2, inclusive, at screening&#xD;
&#xD;
          4. Status : healthy subjects&#xD;
&#xD;
          5. At screening, females must be non-pregnant and non-lactating, or of non-childbearing&#xD;
             potential (either surgically sterilized or physiologically incapable of becoming&#xD;
             pregnant, or at least 1 year post-menopausal [amenorrhoea duration of 12 consecutive&#xD;
             months]); non-pregnancy will be confirmed for all females by a serum pregnancy test&#xD;
             conducted at screening, and a urine pregnancy test at each admission and at follow-up&#xD;
&#xD;
          6. Female subjects of childbearing potential, with a fertile male sexual partner, must&#xD;
             agree to use adequate contraception from screening until 90 days after the follow-up&#xD;
             visit. Adequate contraception is defined as using a non-hormonal intrauterine device&#xD;
             combined with at least 1 of the following forms of contraception: a diaphragm or&#xD;
             cervical cap, or a condom; please note that hormonal contraceptives are not allowed.&#xD;
             Also, total abstinence, in accordance with the lifestyle of the subject, is acceptable&#xD;
&#xD;
          7. Male subjects, if not surgically sterilized, must agree to use adequate contraception&#xD;
             and not donate sperm from admission to the clinical research center until 90 days&#xD;
             after the follow-up visit. Adequate contraception for the male subject (and his female&#xD;
             partner) is defined as using hormonal contraceptives or an intrauterine device,&#xD;
             combined with at least 1 of the following forms of contraception: a diaphragm or&#xD;
             cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of&#xD;
             the subject is acceptable&#xD;
&#xD;
          8. All prescribed medication, including hormonal contraceptives for female subjects, must&#xD;
             have been stopped at least 30 days prior to admission to the clinical research center&#xD;
&#xD;
          9. All over-the-counter medication, vitamin preparations and other food supplements, or&#xD;
             herbal medications (eg, St. John's Wort) must have been stopped at least 14 days prior&#xD;
             to admission to the clinical research center. An exception is made for paracetamol,&#xD;
             which is allowed up to admission to the clinical research center&#xD;
&#xD;
         10. Ability and willingness to abstain from alcohol, methylxanthine-containing beverages&#xD;
             or food (coffee, tea, cola, chocolate, energy drinks) and grapefruit (juice) from 72&#xD;
             hours prior to admission to the clinical research center&#xD;
&#xD;
         11. Good physical and mental health on the basis of medical history, physical examination,&#xD;
             clinical laboratory, electrocardiogram (ECG) and vital signs, as judged by the PI&#xD;
&#xD;
         12. Willing and able to sign the ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Employee of PRA or the Sponsor&#xD;
&#xD;
          2. History of relevant drug and/or food allergies&#xD;
&#xD;
          3. Using tobacco products within 60 days prior to the first drug administration&#xD;
&#xD;
          4. History of alcohol abuse or drug addiction (including soft drugs like cannabis&#xD;
             products)&#xD;
&#xD;
          5. Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including&#xD;
             ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and&#xD;
             alcohol) at screening and admission to the clinical research center&#xD;
&#xD;
          6. Average intake of more than 24 units of alcohol per week (1 unit of alcohol equals&#xD;
             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)&#xD;
&#xD;
          7. Positive screen for hepatitis B surface antigen (HBsAg), anti-HCV antibodies or&#xD;
             anti-human immunodeficiency virus (HIV) 1 and 2 antibodies&#xD;
&#xD;
          8. Participation in a drug study within 60 days prior to the first drug administration in&#xD;
             the current study. Participation in more than 4 other drug studies in the 12 months&#xD;
             prior to the first drug administration in the current study&#xD;
&#xD;
          9. Donation or loss of more than 100 mL of blood within 60 days prior to the first drug&#xD;
             administration. Donation or loss of more than 1.5 liters of blood (for male subjects)&#xD;
             / more than 1.0 liters of blood (for female subjects) in the 10 months prior to the&#xD;
             first drug administration in the current study&#xD;
&#xD;
         10. Significant and/or acute illness within 5 days prior to the first drug administration&#xD;
             that may impact safety assessments, in the opinion of the PI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeroen van de Wetering</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <results_first_submitted>June 10, 2020</results_first_submitted>
  <results_first_submitted_qc>September 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2020</results_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03493698/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03493698/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Each subject was expected to complete treatment groups A, B, C and D; sequentially.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequential Single, Multi-day &amp; Combo Midazolam and Inarigivir</title>
          <description>A: All subjects will receive a single oral dose of 2 mg Midazolam on Day 1&#xD;
B: All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3&#xD;
C: All subjects receive oral dose of 400 mg Inarigivir once daily from Day 6 to Day 18&#xD;
D: All subjects will receive a single oral dose of 400 mg Inarigivir coadministered with a single oral dose of 2 mg Midazolam on Day 19</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period C</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period D</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequential Single, Multi-day &amp; Combo Midazolam and Inarigivir</title>
          <description>A: All subjects will receive a single oral dose of 2 mg Midazolam on Day 1&#xD;
B: All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3&#xD;
C: All subjects receive oral dose of 400 mg Inarigivir once daily from Day 6 to Day 18&#xD;
D: All subjects will receive a single oral dose of 400 mg Inarigivir coadministered with a single oral dose of 2 mg Midazolam on Day 19</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Mean age was 30 years; Individual age ranged between 18 and 46 years</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Individual BMI ranged between 19.3 and 30.0 kg/m2</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (Cmax)</title>
        <description>Comparison of Cmax for midazolam between Treatments A and D.</description>
        <time_frame>Day 1 Treatment A and Day 19 Treatment D, respectively</time_frame>
        <population>All subjects who received at least one dose of midazolam and had sufficient concentration-time data to reliably estimate PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Midazolam</title>
            <description>All subjects will receive a single oral dose of 2 mg Midazolam on Day 1&#xD;
Midazolam: Midazolam</description>
          </group>
          <group group_id="O2">
            <title>Treatment B and C: Inarigivir</title>
            <description>B: All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3&#xD;
C: All subjects receive oral dose of 400 mg Inarigivir once daily from Day 6 to Day 18&#xD;
Inarigivir: Inarigivir</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: Inarigivir With Midazolam</title>
            <description>All subjects will receive a single oral dose of 400 mg Inarigivir coadministered with a single oral dose of 2 mg Midazolam on Day 19&#xD;
Midazolam: Midazolam&#xD;
Inarigivir: Inarigivir</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (Cmax)</title>
          <description>Comparison of Cmax for midazolam between Treatments A and D.</description>
          <population>All subjects who received at least one dose of midazolam and had sufficient concentration-time data to reliably estimate PK parameters</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="6.19" upper_limit="21.4"/>
                    <measurement group_id="O3" value="13.0" lower_limit="7.54" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (AUC0-t)</title>
        <description>Comparison of AUC0-t for midazolam between Treatments A and D.</description>
        <time_frame>Day 1 Treatment A and Day 19 Treatment D, respectively</time_frame>
        <population>This outcome measure was prespecified for treatment groups A and D only.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Midazolam</title>
            <description>All subjects will receive a single oral dose of 2 mg Midazolam on Day 1&#xD;
Midazolam: Midazolam</description>
          </group>
          <group group_id="O2">
            <title>Treatment B and C: Inarigivir</title>
            <description>B: All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3&#xD;
C: All subjects receive oral dose of 400 mg Inarigivir once daily from Day 6 to Day 18&#xD;
Inarigivir: Inarigivir</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: Inarigivir With Midazolam</title>
            <description>All subjects will receive a single oral dose of 400 mg Inarigivir coadministered with a single oral dose of 2 mg Midazolam on Day 19&#xD;
Midazolam: Midazolam&#xD;
Inarigivir: Inarigivir</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (AUC0-t)</title>
          <description>Comparison of AUC0-t for midazolam between Treatments A and D.</description>
          <population>This outcome measure was prespecified for treatment groups A and D only.</population>
          <units>h.ng/ml</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="16.2" upper_limit="57.7"/>
                    <measurement group_id="O3" value="28.7" lower_limit="15.6" upper_limit="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (AUC0-inf )</title>
        <description>Comparison of AUC0-inf for midazolam between Treatments A and D.</description>
        <time_frame>Day 1 Treatment A and Day 19 Treatment D, respectively</time_frame>
        <population>This outcome measure was prespecified for treatment groups A and D only.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Midazolam</title>
            <description>All subjects will receive a single oral dose of 2 mg Midazolam on Day 1&#xD;
Midazolam: Midazolam</description>
          </group>
          <group group_id="O2">
            <title>Treatment B and C: Inarigivir</title>
            <description>B: All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3&#xD;
C: All subjects receive oral dose of 400 mg Inarigivir once daily from Day 6 to Day 18&#xD;
Inarigivir: Inarigivir</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: Inarigivir With Midazolam</title>
            <description>All subjects will receive a single oral dose of 400 mg Inarigivir coadministered with a single oral dose of 2 mg Midazolam on Day 19&#xD;
Midazolam: Midazolam&#xD;
Inarigivir: Inarigivir</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (AUC0-inf )</title>
          <description>Comparison of AUC0-inf for midazolam between Treatments A and D.</description>
          <population>This outcome measure was prespecified for treatment groups A and D only.</population>
          <units>h.ng/ml</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" lower_limit="16.7" upper_limit="61.6"/>
                    <measurement group_id="O3" value="30.5" lower_limit="16.6" upper_limit="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Relevant Clinical Laboratory, Vital Signs, 12-lead ECG, or Physical Examination</title>
        <description>Safety and tolerability were measured via clinical laboratory evaluations, vital signs, 12-lead ECG, or physical examination</description>
        <time_frame>Day -1 to Day 20 and Follow-up (5-9 days post-treatment)</time_frame>
        <population>All participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: Midazolam</title>
            <description>All subjects will receive a single oral dose of 2 mg Midazolam on Day 1&#xD;
Midazolam: Midazolam</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: Inarigivir</title>
            <description>B: All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3&#xD;
Inarigivir: Inarigivir</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: Inarigivir</title>
            <description>C: All subjects receive oral dose of 400 mg Inarigivir once daily from Day 6 to Day 18&#xD;
Inarigivir: Inarigivir</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: Inarigivir With Midazolam</title>
            <description>All subjects will receive a single oral dose of 400 mg Inarigivir coadministered with a single oral dose of 2 mg Midazolam on Day 19&#xD;
Midazolam: Midazolam&#xD;
Inarigivir: Inarigivir</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Relevant Clinical Laboratory, Vital Signs, 12-lead ECG, or Physical Examination</title>
          <description>Safety and tolerability were measured via clinical laboratory evaluations, vital signs, 12-lead ECG, or physical examination</description>
          <population>All participants analyzed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Inarigivir After Single and Multiple Oral Doses in Healthy Subjects (AUC)</title>
        <description>A summary of the main plasma PK parameters for inarigivir, Rp-SB 9000, Sp-SB 9000, and Rp-SB 9000 and Sp-SB 9000 combined after a single oral dose of 400 mg inarigivir on Day 3 (Treatment B) and after the last of 14 consecutive daily oral doses of 400 mg inarigivir from Day 6 to 19 (Treatment D)</description>
        <time_frame>Day 3 and Day 6 to 19</time_frame>
        <population>All subjects in treatment arms B and D who received inarigivir and had sufficient concentration-time data to reliably estimate PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: Inarigivir</title>
            <description>B: All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3&#xD;
Inarigivir: Inarigivir</description>
          </group>
          <group group_id="O2">
            <title>Treatment D: Inarigivir With Midazolam</title>
            <description>All subjects will receive a single oral dose of 400 mg Inarigivir coadministered with a single oral dose of 2 mg Midazolam on Day 19&#xD;
Midazolam: Midazolam&#xD;
Inarigivir: Inarigivir</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Inarigivir After Single and Multiple Oral Doses in Healthy Subjects (AUC)</title>
          <description>A summary of the main plasma PK parameters for inarigivir, Rp-SB 9000, Sp-SB 9000, and Rp-SB 9000 and Sp-SB 9000 combined after a single oral dose of 400 mg inarigivir on Day 3 (Treatment B) and after the last of 14 consecutive daily oral doses of 400 mg inarigivir from Day 6 to 19 (Treatment D)</description>
          <population>All subjects in treatment arms B and D who received inarigivir and had sufficient concentration-time data to reliably estimate PK parameters</population>
          <units>h.ng/ml</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3 AUC0-t (h.ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.914" lower_limit="0.129" upper_limit="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3AUC0-inf (h.ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="0.609" upper_limit="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 19 AUC0-t (h.ng/mL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.951" lower_limit="0.238" upper_limit="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Inarigivir After Single and Multiple Oral Doses in Healthy Subjects (Cmax)</title>
        <description>A summary of the main plasma PK parameters for inarigivir, Rp-SB 9000, Sp-SB 9000, and Rp-SB 9000 and Sp-SB 9000 combined after a single oral dose of 400 mg inarigivir on Day 3 (Treatment B) and after the last of 14 consecutive daily oral doses of 400 mg inarigivir from Day 6 to 19 (Treatment D)</description>
        <time_frame>Day 3 and Day 6 to 19</time_frame>
        <population>All subjects in treatment arms B and D who received inarigivir and had sufficient concentration-time data to reliably estimate PK parameters</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: Inarigivir</title>
            <description>B: All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3&#xD;
Inarigivir: Inarigivir</description>
          </group>
          <group group_id="O2">
            <title>Treatment D: Inarigivir With Midazolam</title>
            <description>All subjects will receive a single oral dose of 400 mg Inarigivir coadministered with a single oral dose of 2 mg Midazolam on Day 19&#xD;
Midazolam: Midazolam&#xD;
Inarigivir: Inarigivir</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Inarigivir After Single and Multiple Oral Doses in Healthy Subjects (Cmax)</title>
          <description>A summary of the main plasma PK parameters for inarigivir, Rp-SB 9000, Sp-SB 9000, and Rp-SB 9000 and Sp-SB 9000 combined after a single oral dose of 400 mg inarigivir on Day 3 (Treatment B) and after the last of 14 consecutive daily oral doses of 400 mg inarigivir from Day 6 to 19 (Treatment D)</description>
          <population>All subjects in treatment arms B and D who received inarigivir and had sufficient concentration-time data to reliably estimate PK parameters</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.886" lower_limit="0.182" upper_limit="2.77"/>
                    <measurement group_id="O2" value="0.991" lower_limit="0.221" upper_limit="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A: Midazolam</title>
          <description>All subjects will receive a single oral dose of 2 mg Midazolam on Day 1&#xD;
Midazolam: Midazolam</description>
        </group>
        <group group_id="E2">
          <title>Treatment B: Inarigivir</title>
          <description>B: All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3&#xD;
Inarigivir: Inarigivir</description>
        </group>
        <group group_id="E3">
          <title>Treatment C: Inarigivir</title>
          <description>C: All subjects receive oral dose of 400 mg Inarigivir once daily from Day 6 to Day 18&#xD;
Inarigivir: Inarigivir</description>
        </group>
        <group group_id="E4">
          <title>Treatment D: Inarigivir With Midazolam</title>
          <description>All subjects will receive a single oral dose of 400 mg Inarigivir coadministered with a single oral dose of 2 mg Midazolam on Day 19&#xD;
Midazolam: Midazolam&#xD;
Inarigivir: Inarigivir</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sensation of Foreign Body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affect Lability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngeal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin Fissures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Don Mitchell, Vice President, Operations &amp; Corporate Development</name_or_title>
      <organization>Spring Bank Pharmaceuticals, Inc.</organization>
      <phone>(508) 689-9737</phone>
      <email>dmitchell@springbankpharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

